P Wagh, S Savaliya, B Joshi,
B Vyas… - Drug Delivery and …, 2024 - Springer
Background Empagliflozin (EMPA) is an SGLT2 inhibitor, a new class of anti-diabetic
medication, indicated for treating type-2 diabetes. Its low permeability, poor solubility and …